-
TOKEN ROI™: A MICRO-COSTING FRAMEWORK FOR DETERMINING WHEN AI IMPROVES HEALTHCARE WORKFLOW ECONOMICS
Mar 18, 2026, 21:38 PM -
VIRTUAL REALITY AS AN ADJUNCTIVE TREATMENT TO OPIOID THERAPY IN PAIN MANAGEMENT AND IMPLICATIONS FOR ADDRESSING THE U.S. OPIOID EPIDEMIC
Mar 18, 2026, 21:38 PM -
A REVIEW ON THE APPLICATION OF PATIENT-REPORTED OUTCOMES IN THE LABELING OF NEW ONCOLOGY DRUGS
Mar 18, 2026, 21:38 PM -
EFFICACY AND EFFECTIVENESS OF IMMUNE CHECKPOINT INHIBITORS IN TRIPLE-NEGATIVE BREAST CANCER: A SYSTEMATIC LITERATURE REVIEW
Mar 18, 2026, 21:38 PM -
FROM DATA TO INSIGHTS: VALIDATING ARTIFICIAL INTELLIGENCE (AI)-GENERATED WRITING IN EVIDENCE SYNTHESIS
Mar 18, 2026, 21:38 PM -
FAMILY IMPACT OF ADULT ANGELMAN SYNDROME: CAREGIVER PERSPECTIVES
Mar 18, 2026, 21:38 PM -
EFFECTIVENESS OF A CENTRALIZED COMMUNITY PHARMACY-BASED PATIENT ACCESS AND THERAPY MANAGEMENT PROGRAM FOR SPECIALTY-LITE MEDICATIONS: A NATIONAL REAL-WORLD STUDY
Mar 18, 2026, 21:38 PM -
REAL-WORLD EFFECTIVENESS OF STATIN THERAPY AND PREDICTIVE MODELING OF ADHERENCE AMONG PATIENTS WITH SEVERE HYPERCHOLESTEROLEMIA
Mar 18, 2026, 21:38 PM -
THE IMPACT OF MEDICATION ADHERENCE ON REAL-WORLD CLINICAL AND ECONOMIC OUTCOMES: A SCOPING REVIEW OF REAL-WORLD EVIDENCE
Mar 18, 2026, 21:38 PM -
VALIDATION OF THE REAL-Q (REAL-WORLD EVALUATION ASSESSMENT LIST FOR QUALITY) TOOL
Mar 18, 2026, 21:38 PM -
SYSTEMATIC LITERATURE REVIEW OF PROGNOSTIC FACTORS AND TREATMENT EFFECT MODIFIERS IN NON-MUSCLE INVASIVE BLADDER CANCER
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF REMIBRUTINIB FOR MODERATE TO SEVERE CHRONIC SPONTANEOUS URTICARIA IN THE U.S.
Mar 18, 2026, 21:38 PM -
ADHERENCE AND PERSISTENCE IN US REAL-WORLD NEW PREP USERS: CABOTEGRAVIR VS EMTRICITABINE/TENOFOVIR ALAFENAMIDE
Mar 18, 2026, 21:38 PM -
COST-BENEFIT ANALYSIS OF TUMOR TREATING FIELDS PLUS RADIOSURGERY FOR BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER
Mar 18, 2026, 21:38 PM -
REAL-TIME AI-ASSISTED LIVING SYSTEMATIC LITERATURE REVIEW (REAL-SLR) CAPTURES A 2025 STANDARD-OF-CARE (SOC) SHIFT DRIVEN BY ANTIBODY-DRUG CONJUGATES (ADCS) IN UROTHELIAL CARCINOMA (UC): IMPLICATIONS FOR HEALTH TECHNOLOGY ASSESSMENTS (HTAS)
Mar 18, 2026, 21:38 PM -
THE ASSOCIATION BETWEEN PNEUMOCOCCAL VACCINATION HISTORY AND THE INCIDENCE OF PNEUMONIA AND HEALTHCARE RESOURSE USE IN RURAL RESIDENTS IN JAPAN
Mar 18, 2026, 21:38 PM -
ECONOMIC IMPACT OF TARDIVE DYSKINESIA AMONG HOSPITALIZED SCHIZOPHRENIA PATIENTS: EVIDENCE FROM US ADMINISTRATIVE DATA
Mar 18, 2026, 21:38 PM -
A MULTI-AGENT GENAI SYSTEM FOR TRACEABLE, MULTI-COUNTRY LANDSCAPE ASSESSMENT IN MASH
Mar 18, 2026, 21:38 PM -
AUTHOR
Mar 18, 2026, 21:38 PM -
COST-CONSEQUENCE ANALYSIS OF UPADACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS IN COLOMBIA
Mar 18, 2026, 21:38 PM
